Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. This morning, we take an inside look at how Moderna and Merck’s cancer vaccine gamble finally paid off, the FTC takes aim at Amgen’s Enbrel patent strategy, and there’s new proto-FDA guidance for generative AI devices….
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk more about Merck and Moderna’s potentially field-changing cancer vaccine, see a couple FDA approvals, and learn more about the new FDA commissioner nominee. Plus, brain organoids have stayed alive — and continue…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Cancer patients may be receiving higher doses and longer courses of expensive drugs than they need. Also, we see Moderna’s stock swing some thanks to profit-taking, and… … I’ve taken to channeling Diogenes these…
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we regale you with mid-August delights from the EMA, ICER, and a federal appeals court. Hope you had a lovely weekend. My kids went to Disneyland, an aquarium, and the beach — but…
National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya, and welcome back to The Readout. Today, we’re getting ready for the FDA’s upcoming decision on Moderna’s mRNA flu shot, and see both a revived fight over 340B rebates and fresh legal scrutiny…
Adobe Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Daniel covers the intersection of…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya. Today, we explore a gene therapy approach that’s drawing excitement but also skepticism, and see that Jennifer Doudna is moving into AI-designed gene editors that push beyond evolution. Plus, our trusty podcasters unpack…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic. Meanwhile, Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, and drugmakers have stepped in to…
